Lazarus Jeffrey V, Brennan Paul N, Mark Henry E, Alazawi William, Allen Alina M, Byrne Christopher D, Castera Laurent, Caussy Cyrielle, Cusi Kenneth, Grajower Martin M, Kopka Christopher J, Massoels Jo, Roden Michael, Spearman C Wendy, Tacke Frank, Wong Vincent Wai-Sun, Noureddin Mazen
City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA.
Barcelona Institute for Global Health (ISGlobal), University of Barcelona, Barcelona, Spain.
Lancet Reg Health Eur. 2025 Jun 4;54:101320. doi: 10.1016/j.lanepe.2025.101320. eCollection 2025 Jul.
Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.
代谢功能障碍相关脂肪性肝炎（MASH）对发病率和死亡率的影响日益显著。目前对其早期诊断和预防不良疾病结局的干预措施重视不足。MASH结局的主要决定因素是肝纤维化阶段。肥胖和/或2型糖尿病患者中MASH的患病率更高，中度至重度纤维化的MASH影响六分之一的成年人。在所研究的四个国家实现MASH诊断的范式转变，需要扩大基于社区的诊断能力，这也将促进预防工作，并为治疗和护理提供机会。
Zotero 插件